Lilly

JHVEPhoto Barron’s said this week that ResMed (NYSE:RMD) trades at a compelling valuation after the stock sold off last month in reaction to positive data for Eli Lilly’s (NYSE:LLY) GLP-1 therapy, tirzepatide, in obstructive sleep apnea, a condition targeted by the MedTech company. In late June, Lilly (LLY) said tirzepatide,Continue Reading

jetcityimage/iStock Editorial via Getty Images Eli Lilly (NYSE:LLY) has named Gordon Brooks as its interim chief financial officer, effective July 15, 2024. Brooks has held various leadership roles during his 29-year career with the company, and currently serves as group VP, controller and corporate strategy. He will replace Anat Ashkenazi,Continue Reading